Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study

ClinicalTrials.gov ID: NCT01516879

Public ClinicalTrials.gov record NCT01516879. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 3:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-Blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Long-Term Tolerability and Durable Efficacy of AMG 145 (Evolocumab) on LDL-C in Hyperlipidemic Subjects

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To evaluate the efficacy, safety, and tolerability of 52 weeks of subcutaneous (SC) evolocumab (AMG 145) compared with placebo when added to assigned background lipid-lowering therapy.

Study identification

NCT ID
NCT01516879
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Amgen
Industry
Enrollment
905 participants

Conditions and interventions

Interventions

Biological · Drug · Other

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 5, 2012 (Actual)
Primary completion
Oct 14, 2013 (Actual)
Completion
Oct 14, 2013 (Actual)
Last update posted
Jul 22, 2022

2012 – 2013

United States locations

U.S. sites
41
U.S. states
25
U.S. cities
36
Facility City State ZIP Site status
Research Site Birmingham Alabama 35216 —
Research Site Little Rock Arkansas 72205 —
Research Site Anaheim California 92801 —
Research Site Encinitas California 92024 —
Research Site Spring Valley California 91978 —
Research Site Westlake Village California 91361 —
Research Site DeLand Florida 32720 —
Research Site Jacksonville Florida 32204 —
Research Site Jacksonville Florida 32216 —
Research Site Ponte Vedra Florida 32081 —
Research Site Atlanta Georgia 30338 —
Research Site Atlanta Georgia 30342 —
Research Site Savannah Georgia 31406 —
Research Site Chicago Illinois 60610 —
Research Site Indianapolis Indiana 46260 —
Research Site Louisville Kentucky 40213 —
Research Site Auburn Maine 04210 —
Research Site Bethesda Maryland 20817 —
Research Site Chevy Chase Maryland 20815 —
Research Site Columbia Maryland 21045 —
Research Site Brockton Massachusetts 02301 —
Research Site Saint Paul Minnesota 55114 —
Research Site Olive Branch Mississippi 38654 —
Research Site Las Vegas Nevada 89148 —
Research Site Endwell New York 13760 —
Research Site New Windsor New York 12553 —
Research Site Raleigh North Carolina 27609 —
Research Site Raleigh North Carolina 27612 —
Research Site Fargo North Dakota 58103 —
Research Site Akron Ohio 44311 —
Research Site Cincinnati Ohio 45219 —
Research Site Cincinnati Ohio 45227 —
Research Site Cincinnati Ohio 45246 —
Research Site Norman Oklahoma 73069 —
Research Site Duncansville Pennsylvania 16635 —
Research Site Mt. Pleasant South Carolina 29464 —
Research Site Rapid City South Dakota 57702 —
Research Site Houston Texas 77030 —
Research Site Richmond Virginia 23294 —
Research Site Renton Washington 98057 —
Research Site Seattle Washington 98104 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 55 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01516879, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 22, 2022 · Synced Oct 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01516879 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →